Alimta® (pemetrexed) – Expanded indication
June 5, 2018 - Eli Lilly announced the FDA approval of Alimta (permetrexed) in combination with carboplatin and Keytruda® (pembrolizumab) for the initial treatment of patients with metastatic, non-squamous non-small cell lung cancer (NSCLC).
Download PDF
